Bellicum Pharmaceuticals, Inc. BLCM
Set alert
0.07 0.00 0.00%
As of Mar 4, 2:59 PM ET
0.0717 Day range 0.09
52-week range unavailable
- Open
- 0.0801
- Prev close
- 0.07475
- Mkt cap
- 778.33K
- Vol
- 6.06K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0717
- High
- 0.09
- Forward P/E
- -0.39
- Beta
- 1.51
- Short ratio
- 0.17
- Inst. own
- 29.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 5, 2024
- 50-d avg
- 0.524896
- 200-d avg
- 0.816478
- 1y target
- 5.00
5Y chart
Events in this range
- Feb 16, 2022Rating: Ladenburg Thalmann · — → Buy
- Nov 10, 2022Earnings: —; estimate 0; surprise —%
- May 11, 2023Earnings: —; estimate 0; surprise —%
- Aug 10, 2023Earnings: —; estimate 0; surprise —%
- Nov 14, 2023Earnings: —; estimate 0; surprise —%
- Mar 5, 2024Earnings: —; estimate 0; surprise —%
Signals (31)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Dec 7, 2023 | 2 years ago |
| SMA: Bullish | Nov 30, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 22, 2023 | 2 years ago |
| MACD: Sell Signal | Oct 24, 2023 | 3 years ago |
| SMA: Bearish | Sep 5, 2023 | 3 years ago |
| SMA: Bullish | Aug 29, 2023 | 3 years ago |
| SMA: Bearish | Aug 22, 2023 | 3 years ago |
| SMA: Bullish | Aug 1, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 18, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 20, 2023 | 3 years ago |
| SMA: Bearish | Jun 6, 2023 | 3 years ago |
| MACD: Buy Signal | May 16, 2023 | 3 years ago |
| SMA: Bullish | May 9, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 14, 2023 | 3 years ago |
| SMA: Bearish | Feb 21, 2023 | 3 years ago |
| SMA: Bullish | Jan 24, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 17, 2023 | 3 years ago |
| SMA: Bullish | Jan 10, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 10, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
Newest 20 of 31.
Analyst view
Consensus: hold
Hold
Price target (mean) 5.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 1
- 2 months ago 1
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.29 | -0.29 – -0.29 | -0.13 | -123.1% | 0 | 0.0% | 1 |
| Next quarter | -0.09 | -0.09 – -0.09 | -0.23 | +60.9% | 0 | 0.0% | 1 |
| Current year | -0.68 | -0.68 – -0.68 | -0.81 | +16.0% | 10.00K | -99.3% | 1 |
| Next year | -0.96 | -0.96 – -0.96 | -0.68 | -41.2% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 16, 2022 | Ladenburg Thalmann | Initiated | — | Buy |
| Nov 25, 2020 | Raymond James | Maintained | — | Outperform |
| Nov 25, 2020 | Citigroup | Maintained | Buy | Buy |
| Nov 25, 2020 | Wells Fargo | Upgrade | Market Perform | Outperform |
| Nov 25, 2020 | Wells Fargo | Downgrade | Outperform | Market Perform |
| Nov 25, 2020 | Raymond James | Maintained | — | Outperform |
| Nov 25, 2020 | Wells Fargo | Initiated | — | Outperform |
| Nov 25, 2020 | Raymond James | Initiated | — | Outperform |
| Nov 25, 2020 | Ladenburg Thalmann | Initiated | — | Buy |
| Nov 25, 2020 | Cantor Fitzgerald | Initiated | — | Buy |
| Nov 25, 2020 | Jefferies | Maintained | — | Buy |
| Nov 25, 2020 | Citigroup | Maintained | — | Neutral |
| Nov 25, 2020 | Citigroup | Upgrade | Neutral | Buy |
| Nov 25, 2020 | SunTrust Robinson Humphrey | Initiated | — | Buy |
| Nov 25, 2020 | Citigroup | Initiated | — | Neutral |
| Nov 25, 2020 | Guggenheim | Upgrade | — | Buy |
| Nov 25, 2020 | Citigroup | Initiated | — | Buy |
| Nov 25, 2020 | Guggenheim | Initiated | — | Neutral |
| Nov 25, 2020 | Citigroup | Maintained | — | Neutral |
| Nov 25, 2020 | PiperJaffray | Initiated | — | Overweight |
| Nov 25, 2020 | Jefferies | Initiated | — | — |
| Oct 30, 2020 | Wells Fargo | Downgrade | Overweight | Equal-Weight |